An Open-label, Phase 2a Trial to Evaluate the Effect of Escalating Doses of IW-1973 on Tolerability, Endothelial Function, and Hemodynamics in Patients With Stable Type 2 Diabetes and Hypertension

Next Previous
Trial Profile

An Open-label, Phase 2a Trial to Evaluate the Effect of Escalating Doses of IW-1973 on Tolerability, Endothelial Function, and Hemodynamics in Patients With Stable Type 2 Diabetes and Hypertension

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs IW 1973 (Primary)
  • Indications Cardiovascular disorders; Diabetic nephropathies
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Ironwood Pharmaceuticals

    • Most Recent Events

    • 04 Dec 2017 Topline results presented in an Ironwood Pharmaceuticals media release.
    • 16 Aug 2017 Status changed from recruiting to completed.
    • 08 May 2017 Data from this trial are expected in the second half of 2017, according to an Ironwood Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top